Buyer support above .50 coming in as well.
Printable View
Big study out in Europe about cancer:
http://www.bbc.co.uk/news/health-24493862
From a purely ethical point of view, the Cx range of products can hopefully lessen this burden both on more accurate/earlier prevention and lower costs. From a capitalist point of view, the Cx range will hopefully go hell for leather sales wise!
Someone is intent on pulling PEB back to .50 each time that it raises its S P up to .53 + I wonder who it could be ?
On that basis traders would be anticipating a very large drop in sales indeed.
It's more about Tindall I think, but as we know traders will follow straight lines to make a humble living. All the better for those looking to top up in a well managed stock at the cusp of years of prospective growth ahead.
After a reasonable amount of research I'm finally in. Modest holding as I'm expecting poor sales in the next announcement but for things to slowly crank after that. Even if it does tank after the next announcement I'm happy to have paid 50c a share as long term I believe its a bargain and happy to be in just in case I'm wrong and the next announcement is positive.
NBT
What constitutes "poor sales"? I am not sure what we should realistically be expecting after less than 6 months. I think less than 50 sales would be a real cause for concern given they have had over 2000 tests done as part of their user-programs, and some of those relationships should have translated into sales. But what about 100 sales? 200? I am not really sure what will be a good or bad result come the report :S
You must wonder about their motivations more... someone keeping the price down in preparation for a takeover offer? Purely speculation but I wouldn't put it past a big international biotech who wanted to take over a very innovative and game changing biotech company... again purely speculation but one must wonder!
I feel the next report will set the benchmark for sales - i.e. the annualised version (i.e. sales amount x2 because it was only 6 months) will be the basis for them to be able to say "we have doubled/tripled/quadrupled sales" for the next year. I can't imagine it being amazing, my gut feeling though is around 3-5k sales in the US will be a pretty good result. More interesting for me though will be the NZ uptake - this will/should indicate the uptake overseas. NZ is often the test market for many things and we have doctors that are just as good as those in the US and work in the same western medicine paradigm. The two places have completely different regulatory and funding models, which may make a difference, but in the end I think they will probably end up doing a similar amount of testing. So my feeling is that if there is a good uptake in NZ/AUS, it will eventually flow through to a good uptake in the US. If they report that the DHBs here are signing up to support the product, that will be a massive indicator for the future for LUGs signing up in the US. So far, it sounds like the DHBs here are very supportive which I take as a very good sign.